029 Group SE

Earnings Release • May 31, 2006

News Details

Ad-hoc | 31 May 2006 07:51

Rhein Biotech N.V. reports 2005 Full Year results

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Maastricht, May 31, 2006 Rhein Biotech N.V. reports for the Full Year 2005 total sales of 28.7 million Euro. The EBITDA was 0.1 million Euro, while the loss from operations (EBIT) was –4.2 million Euro. Rhein Biotech’s loss for the period 2005 was –3.9 million Euro. The Company’s cash position at the end of December 2005 was 22.6 million Euro. This is the Company’s first consolidated income statement prepared in accordance with IFRS. The full report is available on www.rheinbiotech.com Consolidated income statement for the year ending December 31, 2005 IFRS, Amounts in EUR ‘000.: 2005 Revenue: 28’680 Loss from operations (EBIT): – 4’207 Net financing costs: – 229 Gain on sale of consolidated companies: 543 Share of result of joint ventures: – 3 Loss before tax: -3’896 Income tax expense: -10 Loss for the period: – 3 906 Crucell N.V. Harry Suykerbuyk Director Investor Relations and Corporate Communications Tel. +31-(0)71-524 8718 h.suykerbuyk@crucell.com (c)DGAP 31.05.2006 ————————————————————————— Language: English Issuer: Rhein Biotech N.V. Oude Maasstraat 47 6229 BC Maastricht Niederlande Phone: +31 433 56 78 9-0 Fax: +31 433 56 78 9-9 email: patrik.richard@bernabiotech.com WWW: www.bernabiotech.com ISIN: NL0000230324 WKN: 919544 indices: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Stuttgart, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————